Short name: MION, central moiety: Fe3+/Fe2+, relaxivity: r1=3.7, r2=6.5, B0=0.47T
MIONs are under development (preclin.) as contrast agents (taken up by the RES) for MR angiography, MR lymphography, tumor detection and detection of infarctioned tissue. Also called monodisperse iron oxide nanoparticles or nanocompounds.

Contrast agent with a preferential intracellular distribution.
Intracellular agents (such as manganese derivatives and ultrasmall superparamagnetic iron oxide), exhibit a flow- and metabolism-dependent uptake. These properties may allow delayed imaging, similar to isotopic methods.
Phospholipid liposomes are rapidly sequestered by the cells in the reticuloendothelial system (RES), primarily in the liver. For imaging of the liver, liposomes may be labeled with MR contrast medium, both positive (T1-shortening) paramagnetic media, and negative (T2-shortening) superparamagnetic media.
Several other nonliposome MR contrast media are also taken up by the RES, e.g.:
Other MR contrast agents accumulate selectively in the hepatocytes, e.g.:

Molecular Imaging is a new diagnostic discipline to visualize biological processes.
Molecular magnetic resonance imaging (mMRI) offers the potential to image tissues at the cellular and subcellular level. Targeted MR contrast agents enhance the diagnostic specificity and range of molecular magnetic resonance imaging.
Other modalities that can be used for noninvasive molecular imaging:

See also Nanoparticle, Monocrystalline Iron Oxide Nanoparticle, Polycrystalline Iron Oxide Nanoparticles, Liposomes, Monoclonal Antibodies, Bimodal Imaging, Tumor Specific Agents, and Intracellular Contrast Agents.